Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-019319

Viridian Therapeutics, Inc.\DE · VRDN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Kyle Lefkoff
Director
Period of report
Mar 6, 2017
Accepted (ET)
Mar 8, 2017 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Mar 6, 2017S9,392$15.7144D474,881ISee Footnote
Common StockF3,F2Mar 6, 2017S608$16.2398D474,273ISee Footnote
Common StockF4,F2Mar 8, 2017S5,000$14.7028D469,273ISee Footnote
Common StockF5holding———1,607,437ISee Footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses